Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

A Boston startup hoping to block cancer cells' ability to ward off the body's immune system just signed its second major pharmaceutical deal, announcing an $80 million partnership Friday to develop two treatments with drug giant Celgene.